Nublexa Tablet

Nublexa 40mg (Regorafenib) is an ingenious drug recommended for patients with cancer of colon and rectum (parts of the large intestine). Scientifically, Nublexa 40 mg (Regorafenib) is indicated for metastatic colorectal cancer (CRC) who were given chemotherapeutics beforehand. If CRC is left untreated, it could spread throughout the body. Additionally, Nublexa 40 mg (Regorafenib) is also specified for patients with gastrointestinal stromal tumors (Cancer of stomach and intestine) and liver cancer who were given anti-cancer therapies (imatinib and sorafenib) earlier.

Regorafenib has multi-action potential wherein it stops various proteins involved in,

1. Normal functioning of cancer cells (Cell-stability)
2. Progression of cancer cells (Oncogenesis)
3. Blood flow to cancer cells (Angiogenesis)
4. Growth and multiplication of cancer cells (Cell-proliferation)

Administration of Nublexa 40 mg (Regorafenib):

Nublexa 40mg (Regorafenib) is recommended orally at the dosage of 160 mg (4×40mg tablets) which is taken for 21 days in a 28-day dosage cycle. In this 28-day cycle, the final 7 days are laid off to seek any sort of improvements or changes after administration. 80 mg (2×40mg tablets) is the lowest recommended dose whereas 160 mg is the highest recommended dose for a single day. Once swallowed, about 83% of the drug is readily available for absorption (bio-available) within 3 to 4 hours. Regorafenib has a high binding affinity (99.5%) with cancer cells which assists in distributing its contents throughout the region of cancer. Furthermore, regorafenib is metabolized in the liver and finally expelled (90%) from the body in 12 days after administration. If patients’ vomit after taking regorafenib, they shouldn’t take the supplementary tablets and inform their respective healthcare provider immediately.

When should Nublexa 40 mg (Regorafenib) be avoided or used cautiously?

• If patients have abnormal results [abnormal levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin] in liver tests, dose modification is recommended
• If patients have a high incidence of infections
• If patients have a high risk of bleeding problems (hemorrhage), blood testing should be done regularly
• If patients have started to develop an infection in the stomach and intestinal regions (gastrointestinal perforation or fistula)
• If patients suffer from heart problems (heart attack or failure, ischemic heart disease)
• If patients have abnormal levels of blood pressure (hypertension), it should be monitored regularly
• If patients are undergoing any sort of surgical operations
• If there are incidences of rashes and skin reactions (hand-foot skin reaction (HFSR))
• If patients are suffering from kidney cancer (hepatocellular carcinoma)
• Regorafenib contains 1.68 mg of soya compound (lecithin) in 160 mg of dose. If the patients are intolerant to lactose or soya, it should be mentioned beforehand

Most common side-effects of Nublexa 40 mg (Regorafenib):

• Problems in the stomach like diarrhea and intestinal infection
• Skin reactions like rashes and HFSR
• Low levels of platelets (Thrombocytopenia)
• Low levels of red blood cells (Anemia)
• Tiredness or fatigue (Asthenia)
• Loss of hunger leading to inadequate food intake and weight loss
• Harsh voice (Dysphonia)
• High blood pressure
• Inflammation in the mouth (Stomatitis)
• Ulcer in the mouth (Mucositis)

Note: These are not all possible side-effects of Nublexa 40mg (Regorafenib), please ask your doctor for more information regarding the same.

Nublexa 40mg (Regorafenib) is also available in these countries: (South East Asia, South America, Eastern Europe, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Macedonia, Poland, Republic of Kosovo, Republic of Moldova, Romania, Russia, Serbia, Slovak Republic, Slovenia, Malaysia, Indonesia, Philippines, Venezuela and Korea.) and many more…